Business Context and Reporting Period
This Form 6-K filing by Banco Bradesco S.A. (Bradesco) relates to an Extraordinary General Meeting scheduled for March 31, 2026. The filing serves as an attendance manual and call notice for shareholders to vote on a partial spin-off of Bradseg Participações S.A. ("Bradseg"), a wholly-owned subsidiary of Bradesco. The transaction is the initial step in a broader business combination designed to consolidate Bradesco's healthcare ecosystem under Odontoprev S.A. ("Odontoprev"). The financial data referenced in the filing is based on the period ending December 31, 2025.
Key Financial Metrics
The filing provides specific valuation figures for the corporate restructuring but does not contain Bradesco's consolidated revenue, profit, or cash flow statements for the period. Key financial data points include:
- Valuation of Spun-Off Portion: The net assets to be transferred from Bradseg to Bradesco are valued at R$ 16,136,310,439.65 (as of December 31, 2025). This includes R$ 15,413,562,899.08 in Bradesco Gestão de Saúde S.A. (BGS) shares and R$ 722,747,540.57 in Odontoprev shares.
- Bradesco Shareholders' Equity: As of December 31, 2025, Bradesco's total equity is R$ 172,239,039,499.00.
- Bradesco Share Capital: Current share capital is R$ 87,100,000,000.00. An ongoing capital increase of R$ 6,670,000,000.00 (capitalization of profit reserves) is pending approval, which would raise total capital to R$ 93,770,000,000.00.
- Bradseg Share Capital: Pre-spin-off capital is R$ 19,352,673,355.70. Post-spin-off, it will be reduced to R$ 2,266,739,994.64.
- Transaction Costs: Estimated costs for the spin-off are approximately R$ 300,000.00. KPMG fees for the appraisal report total R$ 40,000.00.
The filing does not provide specific values for revenue, net profit, operating margins, debt levels, or liquidity ratios for the reporting period.
Material Changes and Corporate Actions
The primary material change is the proposed partial spin-off of Bradseg, which will result in the absorption of specific assets (BGS and Odontoprev shares) by Bradesco. Key characteristics of this change include:
- No Dilution: The transaction will not result in an increase in Bradesco's share capital or the issuance of new shares, as Bradesco already owns 100% of Bradseg.
- Capital Reduction: Bradseg's share capital will be reduced by R$ 17,085,933,361.06.
- Strategic Consolidation: The move aims to simplify the corporate structure and unify healthcare and dental solutions under Odontoprev, enhancing administrative efficiency.
Outlook, Risks, and Management Commentary
Management views the transaction as a significant step in the evolution of the Bradesco Organization's corporate structure, intended to create a unified healthcare ecosystem with soundness and profitability. The filing notes that the transaction is subject to customary risks, including price variations of shares following disclosure. No specific financial guidance or outlook regarding future revenue or earnings is provided in this document. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to economic and market conditions.
Investor Verification Checklist
- Verify the approval status of the "Ongoing Capital Increase" (R$ 6.67 billion) mentioned as pending Central Bank confirmation.
- Confirm the final implementation date of the Bradseg Partial Spin-Off following the March 31, 2026, shareholder vote.
- Review the full Appraisal Report by KPMG Auditores Independentes Ltda. to understand the valuation methodology for the R$ 16.1 billion asset transfer.
- Monitor subsequent filings for the consolidated financial impact of the transaction on Bradesco's balance sheet and income statement.
- Check for any dissenting shareholder actions or regulatory hurdles regarding the merger of BGS and Odontoprev.